Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PRAH - PRA Health Sciences Inc


Close
165.21
-2.800   -1.695%

Share volume: 0
Last Updated: Wed 30 Jun 2021 10:00:01 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$168.01
-2.80
-1.67%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
22%
Profitability 25%
Dept financing 20%
Liquidity 25%
Performance 20%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$165.21
P/E Ratio 
0.00
DAY RANGE
$165.21 - $165.21
EPS 
$3.27
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
64.795 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO:
Region: US
Website: www.prahs.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

PRA is one of the world's leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 18,100 employees worldwide. Since 2000, PRA has participated in approximately 4,200 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 100 drugs.

Recent news